[From willow bark to the coxibs. Development of antiphlogistic analgesics].
Antiphlogistic analgesics comprise the most widely used class of drugs worldwide. These compounds derive more or less directly from three prototypes which were discovered about 130 years ago in Central Europe: acetylsalicylic acid (aspirin), acetanilide (the forerunner of acetaminophen), and phenazone. All of them are still available. Attempts to improve their effect/side effect spectrum and enhance their analgesic activity led to the development of animal models of inflammatory pain which allowed for the screening and discovery of the so-called aspirin-like drugs, also termed nonsteroidal antiinflammatory drugs (NSAIDs) or cyclooxygenase inhibitors. This group presently dominates the market despite the fact that all these compounds imply the risk of unwanted drug effects, including gastrointestinal ulcers, renal dysfunction, inhibition of blood coagulation, pseudoallergic reactions, and possibly also accelerated development of atherosclerosis. Attempts to reduce these unwanted drug effects on the basis of molecular pharmacological insights resulted in the development of the so-called selective cyclooxygenase-2 inhibitors which are presently discussed ambiguously. These compounds appear to go along with less gastrointestinal toxicity, they do not inhibit blood coagulation, and have a reduced propensity for causing pseudoallergic asthmatic attacks. They may, on the other hand, cause more unwanted cardiovascular effects than the traditional NSAIDs. Hope for further reduction of unwanted drug effects comes from the recently discovered role of glycinergic spinal pain control. It is hoped that new classes of analgesic compounds may result from these new glycinergic mechanisms.
Brune
K
K
Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Deutschland. brune@pharmakologie.med.uni-erlangen.de
Niederweis
U
U
D000083:Acetanilides / Q000009:adverse effects / Q000266:history / Q000627:therapeutic use; D000700:Analgesics / Q000009:adverse effects / Q000266:history* / Q000627:therapeutic use*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000266:history* / Q000627:therapeutic use*; D000983:Antipyrine / Q000009:adverse effects / Q000266:history / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects / Q000266:history / Q000627:therapeutic use; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000266:history* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005060:Europe; D049672:History, 19th Century; D006801:Humans; D010146:Pain / Q000188:drug therapy* / Q000266:history; D008517:Phytotherapy; D024301:Plant Bark; D051381:Rats; D032108:Salix
D000083:Acetanilides; D000700:Analgesics; D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D001241:Aspirin; C508827:acetanilide; D000983:Antipyrine